PT-141 and HSDD

RECONNECT

Two Phase 3 trials published in 2019 enrolled 1,267 premenopausal women with acquired, generalised hypoactive sexual desire disorder, or HSDD. Desire had declined after being present earlier; the loss persisted across settings and caused distress. Over 24 weeks, bremelanotide improved desire and reduced desire-related distress compared with placebo. Both planned primary outcomes were met in both trials.

I value the distress measure. More desire has a different significance when the loss is upsetting the person experiencing it. The US prescribing information covers this specific condition before menopause. Men, women after menopause and sexual-performance claims sit outside that approval. Research-labelled PT-141 material also sits outside the approved drug’s quality framework.

The 31-woman MRI study

PT-141 is the research name for bremelanotide, a synthetic peptide whose seven amino acids form a ring. It was developed from a melanocortin relative first explored for tanning, with later development focusing on sexual function. Its proposed action engages brain receptors involved in sexual motivation.

In the 2022 crossover study of 31 women with HSDD, each woman received active treatment and placebo in separate periods, in a randomly assigned order. Neither participants nor investigators knew the treatment at the time. Desire increased for up to 24 hours, while MRI measured altered responses to erotic material and stronger functional connections between the amygdala and insula, regions involved in emotion and bodily sensation.

I like bremelanotide’s brain-scan work best when it stays close to the reported experience. The scan gives the brain mechanism substance; the women’s answers remain essential to knowing whether the experience changed.

Hamster place-preference testing

A 2025 experiment in female Syrian hamsters asked about sexual reward through preference for a place associated with sex. Neither tested amount enhanced that preference or changed melanocortin-receptor mRNA readings in the studied dopamine system. The animal finding concerns the rewarding aspect of sexual interaction.

Wanting, arousal, pleasure and distress can move separately. I regard PT-141’s effects on each as a separate question. The hamster result adds a useful complication without overturning what women reported in the human trials.

Nausea, circulation and skin colour

In the 52-week open-label extension, 684 women enrolled. Desire improvements were sustained and no new safety signals emerged. Everyone knew the treatment, which makes expectation harder to separate from effect. Drug-related adverse events included nausea in 40.4%, flushing in 20.6% and headache in 12.0%. Nausea was a major tolerability problem.

The prescribing information warns about a temporary blood-pressure rise, accompanied by a small heart-rate decrease. It contraindicates use with uncontrolled hypertension or known cardiovascular disease. It also describes darkening of the face, gums and breasts with frequent use; some pigmentation may persist after stopping. Safety in pregnancy and breastfeeding is unsupported.

Product identity and purity remain additional concerns with unverified research material. Its effects and risks cannot be assumed to match a verified prescription preparation.

Community accounts

Anecdotal reports describe increased interest, greater sensitivity, easier orgasm or a sense of closeness. Other people describe no desired change while still experiencing adverse effects. These accounts are personal reports, without controlled clinical evidence behind each claimed effect. They also include men using PT-141 outside approval.

Nausea, flushing, headache, injection-site irritation, tingling and drowsiness recur in those accounts. Feeling worse without the hoped-for benefit is a particularly unattractive possibility. The clinical nausea data make that possibility quite tangible; the personal stories cannot establish how often it happens.